TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival
Grace Lassiter(Massachusetts General Hospital), Tatsuo Kawai(Harvard University), Ahmad Karadagi(Karolinska University Hospital), Zahida Ali(Charles River Laboratories (United States)), Robert B. Colvin(Harvard University), Seth Lederman(Eloxx Pharmaceuticals (United States)), Bruce Daugherty(Eloxx Pharmaceuticals (United States)), Phil Berhe(Charles River Laboratories (United States)), Toshihide Tomosugi(Harvard University), Takayuki Hirose(Harvard University), Anna N. Moraitis(National Academies of Sciences, Engineering, and Medicine), Bernd Meibohm(University of Tennessee Health Science Center), Jason Baardsnes(Queen's University), Emma E. Smith(National Academies of Sciences, Engineering, and Medicine), Richard N. Pierson(Harvard University), Siobhan Fogarty(Eloxx Pharmaceuticals (United States)), Ryo Otsuka(Hokkaido University), A. Dehnadi(Harvard University), Hang Lee(Massachusetts General Hospital), Ivy A. Rosales(Harvard University)
Cited by 30
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
|The Journal of Clinical Endocrinology & Metabolism|2007|1.6k